Metformin inhibits tumor growth by regulating multiple miRNAs in human cholangiocarcinoma

Oncotarget

Volumn 6, Issue 5, 2015, Pages 3178-3194

  Jiang, Xingming ^a   Ma, Ning ^b   Wang, Dayong ^b   Li, Fuyuan ^b   He, Rongzhang ^b   Li, Dongliang ^b   Zhao, Ruiqi ^b   Zhou, Qingxin ^a   Wang, Yimin ^a   Zhang, Fumin ^a   Wan, Ming ^a   Kang, Pengcheng ^a   Gao, Xu ^b   Cui, Yunfu ^a  

^a THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Cell cycle; Cholangiocarcinoma; Metformin; microRNA; Prognosis

Indexed keywords

METFORMIN; MICRORNA; MICRORNA 124; MICRORNA 181A; MICRORNA 182; MICRORNA 221; MICRORNA 27B; MICRORNA LET7B; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; DROSHA PROTEIN, HUMAN; RIBONUCLEASE III;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT CARCINOMA; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE ARREST; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; POSTOPERATIVE PERIOD; PREDICTION; TUMOR VOLUME; UPREGULATION; ANIMAL; BILE DUCT NEOPLASMS; CELL CYCLE CHECKPOINT; CHOLANGIOCARCINOMA; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; NUDE MOUSE; TIME FACTOR; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BILE DUCT NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLANGIOCARCINOMA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOGLYCEMIC AGENTS; KAPLAN-MEIER ESTIMATE; METFORMIN; MICE, NUDE; MICRORNAS; RIBONUCLEASE III; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84923267074     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3063     Document Type: Article

References (46)

1. De Groen PC, Gores GJ, LaRusso NF, Gunderson LL and Nagorney DM. Biliary tract cancers. The New England journal of medicine. 1999; 341(18):1368-1378.
2. Khan SA, Thomas HC, Davidson BR and Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005; 366(9493):1303-1314.
3. Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA and Kurzrock R. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget. 2013; 4(1):153-162.
4. Shaib Y and El-Serag HB. The epidemiology of cholangiocarcinoma. Seminars in liver disease. 2004; 24(2):115-125.
5. Malhi H and Gores GJ. Cholangiocarcinoma: modern advances in understanding a deadly old disease. Journal of hepatology. 2006; 45(6):856-867.
6. Witters LA. The blooming of the French lilac. The Journal of clinical investigation. 2001; 108(8):1105-1107.
7. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y and Bost F. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008; 27(25):3576-3586.
8. Del Barco S, Vazquez-Martin A, Cufi S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J, Martin-Castillo B and Menendez JA. Metformin: multi-faceted protection against cancer. Oncotarget. 2011; 2(12):896-917.
9. Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer discovery. 2012; 2(9):778-790.
10. Chaiteerakij R, Yang JD, Harmsen WS, Slettedahl SW, Mettler TA, Fredericksen ZS, Kim WR, Gores GJ, Roberts RO, Olson JE, Therneau TM and Roberts LR. Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology. 2013; 57(2):648-655.
11. Li D, Yeung SC, Hassan MM, Konopleva M and Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology. 2009; 137(2):482-488.
12. Avci CB, Harman E, Dodurga Y, Susluer SY and Gunduz C. Therapeutic potential of an anti-diabetic drug, metformin: alteration of miRNA expression in prostate cancer cells. Asian Pacific journal of cancer prevention: APJCP. 2013; 14(2):765-768.
13. Feng Y, Ke C, Tang Q, Dong H, Zheng X, Lin W, Ke J, Huang J, Yeung SC and Zhang H. Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling. Cell death & disease. 2014; 5:e1088.
14. Liu J, Li M, Song B, Jia C, Zhang L, Bai X and Hu W. Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft. Urologic oncology. 2013; 31(2):264-270.
15. Gao LB, Tian S, Gao HH and Xu YY. Metformin inhibits glioma cell U251 invasion by downregulation of fibulin-3. Neuroreport. 2013; 24(10):504-508.
16. Cerezo M, Tichet M, Abbe P, Ohanna M, Lehraiki A, Rouaud F, Allegra M, Giacchero D, Bahadoran P, Bertolotto C, Tartare-Deckert S, Ballotti R and Rocchi S. Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner. Molecular cancer therapeutics. 2013; 12(8):1605-1615.
17. Giordano S and Columbano A. MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology. 2013; 57(2):840-847.
18. Ambros V. microRNAs: tiny regulators with great potential. Cell. 2001; 107(7):823-826.
19. Chang Y, Liu C, Yang J, Liu G, Feng F, Tang J, Hu L, Li L, Jiang F, Chen C, Wang R, Yang Y, Jiang X, Wu M, Chen L and Wang H. MiR-20a triggers metastasis of gallbladder carcinoma. Journal of hepatology. 2013; 59(3):518-527.
20. Gao L, Wang X, Wang X, Zhang L, Qiang C, Chang S, Ren W, Li S, Yang Y, Tong D, Chen C, Li Z, Song T, Zhi K and Huang C. IGF-1R, a target of let-7b, mediates crosstalk between IRS-2/Akt and MAPK pathways to promote proliferation of oral squamous cell carcinoma. Oncotarget. 2014; 5(9):2562-2574.
21. Chakravarthi BV, Pathi SS, Goswami MT, Cieslik M, Zheng H, Nallasivam S, Arekapudi SR, Jing X, Siddiqui J, Athanikar J, Carskadon SL, Lonigro RJ, Kunju LP, Chinnaiyan AM, Palanisamy N and Varambally S. The miR-124-prolyl hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression. Oncotarget. 2014; 5(16):6654-6669.
22. Khan S, Ebeling MC, Zaman MS, Sikander M, Yallapu MM, Chauhan N, Yacoubian AM, Behrman SW, Zafar N, Kumar D, Thompson PA, Jaggi M and Chauhan SC. MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer. Oncotarget. 2014; 5(17):7599-7609.
23. Kobayashi M, Kato K, Iwama H, Fujihara S, Nishiyama N, Mimura S, Toyota Y, Nomura T, Nomura K, Tani J, Miyoshi H, Kobara H, Mori H, Murao K and Masaki T. Antitumor effect of metformin in esophageal cancer: in vitro study. International journal of oncology. 2013; 42(2):517-524.
24. Kato K, Gong J, Iwama H, Kitanaka A, Tani J, Miyoshi H, Nomura K, Mimura S, Kobayashi M, Aritomo Y, Kobara H, Mori H, Himoto T, Okano K, Suzuki Y, Murao K, et al. The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Molecular cancer therapeutics. 2012; 11(3):549-560.
25. Li W, Yuan Y, Huang L, Qiao M and Zhang Y. Metformin alters the expression profiles of microRNAs in human pancreatic cancer cells. Diabetes research and clinical practice. 2012; 96(2):187-195.
26. Bao B, Wang Z, Ali S, Ahmad A, Azmi AS, Sarkar SH, Banerjee S, Kong D, Li Y, Thakur S and Sarkar FH. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer prevention research. 2012; 5(3):355-364.
27. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, Liu CG, Bhatt D, Taccioli C and Croce CM. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA: the journal of the American Medical Association. 2007; 297(17):1901-1908.
28. Yang X, Zhang XF, Lu X, Jia HL, Liang L, Dong QZ, Ye QH and Qin LX. MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway. Hepatology. 2014; 59(5):1874-1885.
29. Jiang J, Sun X, Wang W, Jin X, Bo X, Li Z, Bian A, Jiu J, Wang X, Liu D, Hui X, Wang Y, Wang A and Ding L. Tumor microRNA-335 expression is associated with poor prognosis in human glioma. Medical oncology. 2012; 29(5):3472-3477.
30. Guo X, Liao Q, Chen P, Li X, Xiong W, Ma J, Li X, Luo Z, Tang H, Deng M, Zheng Y, Wang R, Zhang W and Li G. The microRNA-processing enzymes: Drosha and Dicer can predict prognosis of nasopharyngeal carcinoma. Journal of cancer research and clinical oncology. 2012; 138(1):49-56.
31. Fang Y, Xue JL, Shen Q, Chen J and Tian L. MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma. Hepatology. 2012; 55(6):1852-1862.
32. Satoh M, Minami Y, Takahashi Y, Tabuchi T and Nakamura M. A cellular microRNA, let-7i, is a novel biomarker for clinical outcome in patients with dilated cardiomyopathy. Journal of cardiac failure. 2011; 17(11):923-929.
33. Wang S, Li Q, Wang K, Dai Y, Yang J, Xue S, Han F, Zhang Q, Liu J and Wu W. Decreased expression of microRNA-31 associates with aggressive tumor progression and poor prognosis in patients with bladder cancer. Clinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2013; 15(10):849-854.
34. Goto Y, Kojima S, Nishikawa R, Enokida H, Chiyomaru T, Kinoshita T, Nakagawa M, Naya Y, Ichikawa T and Seki N. The microRNA-23b/27b/24-1 cluster is a disease progression marker and tumor suppressor in prostate cancer. Oncotarget. 2014; 5(17):7748-7759.
35. Ha M and Kim VN. Regulation of microRNA biogenesis. Nature reviews Molecular cell biology. 2014.
36. Lund E, Guttinger S, Calado A, Dahlberg JE and Kutay U. Nuclear export of microRNA precursors. Science. 2004; 303(5654):95-98.
37. Lee TY, Ezelle HJ, Venkataraman T, Lapidus RG, Scheibner KA and Hassel BA. Regulation of human RNase-L by the miR-29 family reveals a novel oncogenic role in chronic myelogenous leukemia. Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research. 2013; 33(1):34-42.
38. Han J, Lee Y, Yeom KH, Kim YK, Jin H and Kim VN. The Drosha-DGCR8 complex in primary microRNA processing. Genes & development. 2004; 18(24):3016-3027.
39. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O, Kim S and Kim VN. The nuclear RNase III Drosha initiates microRNA processing. Nature. 2003; 425(6956):415-419.
40. Schmittgen TD, Jiang J, Liu Q and Yang L. A high-throughput method to monitor the expression of microRNA precursors. Nucleic acids research. 2004; 32(4):e43.
41. Parikh A, Lee C, Peronne J, Marchini S, Baccarini A, Kolev V, Romualdi C, Fruscio R, Shah H, Wang F, Mullokandov G, Fishman D, D'Incalci M, Rahaman J, Kalir T, Redline RW, et al. microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nature communications. 2014; 5:2977.
42. Maurin T, Cazalla D, Yang S, Jr., Bortolamiol-Becet D and Lai EC. RNase III-independent microRNA biogenesis in mammalian cells. Rna. 2012; 18(12):2166-2173.
43. Han J, Lee Y, Yeom KH, Nam JW, Heo I, Rhee JK, Sohn SY, Cho Y, Zhang BT and Kim VN. Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex. Cell. 2006; 125(5):887-901.
44. Ma N, Li F, Li D, Hui Y, Wang X, Qiao Y, Zhang Y, Xiang Y, Zhou J, Zhou L, Zheng X and Gao X. Igf2-derived intronic miR-483 promotes mouse hepatocellular carcinoma cell proliferation. Molecular and cellular biochemistry. 2012; 361(1-2):337-343.
45. Li F, Ma N, Zhao R, Wu G, Zhang Y, Qiao Y, Han D, Xu Y, Xiang Y, Yan B, Jin J, Lv G, Wang L, Xu C, Gao X and Luo S. Overexpression of miR-483-5p/3p cooperate to inhibit mouse liver fibrosis by suppressing the TGF-beta stimulated HSCs in transgenic mice. Journal of cellular and molecular medicine. 2014.
46. Xiang Y, Ma N, Wang D, Zhang Y, Zhou J, Wu G, Zhao R, Huang H, Wang X, Qiao Y, Li F, Han D, Wang L, Zhang G and Gao X. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene. 2014; 33(3):378-386.